MaxCyte NAQ receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MaxCyte Inc (MXCT)
MaxCyte Inc stock price live, this page displays NASDAQ MXCT stock exchange data. View the MXCT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the MaxCyte Inc real time stock price chart below.
What Is the MaxCyte Inc Stock Price Today?
The MaxCyte Inc stock price today is 2.240.
What Is the Stock Symbol for MaxCyte Inc?
The stock symbol for MaxCyte Inc is ""MXCT.""
What Stock Exchange Does MaxCyte Inc Trade On?
MaxCyte Inc is listed and trades on the NASDAQ stock exchange.
Is MaxCyte Inc a Good Stock to Buy?
Determining whether MaxCyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MXCT quote. (ISIN: US57777K1060)
What Is the MaxCyte Inc Stock Price Today?
The MaxCyte Inc stock price today is 2.240.
What Is the Stock Symbol for MaxCyte Inc?
The stock symbol for MaxCyte Inc is ""MXCT.""
What Stock Exchange Does MaxCyte Inc Trade On?
MaxCyte Inc is listed and trades on the NASDAQ stock exchange.
Is MaxCyte Inc a Good Stock to Buy?
Determining whether MaxCyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MXCT quote. (ISIN: US57777K1060)
2.240
+0.140(+6.67%)
Closed·
After Hours
2.210-0.030(-1.34%)
·
Fair Value
An estimate of a MaxCyte's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.120
2.295
52 wk Range
2.000
5.200
MXCT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 14 days
More Info
Fair Value
An estimate of a MaxCyte's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1202.295
52 wk Range
2.0005.200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MXCT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a MaxCyte's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
6.750
Upside
+201.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
- Form 8K MaxCyte Inc For: 18 June
- Investing.com
- Form 8K MaxCyte Inc For: 25 June
- Investing.com
- MaxCyte NAQ receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K MaxCyte Inc For: 25 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
MaxCyte Inc Company Profile
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte Inc Earnings Call Summary for Q1/2025
- MaxCyte Q1 2025 revenue beats forecast at $10.4M, EPS at -$0.10 vs -$0.11 expected; stock falls 2.92% in aftermarket trading
- Core revenue up 1% YoY; operating expenses down to $21.2M; company maintains strong liquidity with $174.7M cash and investments
- 2025 core revenue growth guidance reaffirmed at 8-15%; expects to end year with ~$160M cash, positioning for future growth
- CEO highlights strategic focus on cell and gene therapy market expansion; recent acquisitions like SecureDx to drive growth
- Analysts express concerns over capital spending trends; management acknowledges some hesitation but remains cautiously optimistic
Last Updated: 07/05/2025, 22:20
Read Full TranscriptCompare MXCT to Peers and Sector
Metrics to compare | MXCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMXCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.7x | −0.7x | −0.5x | |
PEG Ratio | 0.43 | 0.07 | 0.00 | |
Price/Book | 1.2x | 1.1x | 2.6x | |
Price / LTM Sales | 6.3x | 3.8x | 3.2x | |
Upside (Analyst Target) | 209.5% | 99.5% | 42.7% | |
Fair Value Upside | Unlock | 12.6% | 5.8% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.750
(+201.34% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
-0.10 / -0.11
Revenue / Forecast
10.40M / 9.05M
People Also Watch
FAQ
What Stock Exchange Does MaxCyte Trade On?
MaxCyte is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for MaxCyte?
The stock symbol for MaxCyte is "MXCT."
What Is the MaxCyte Market Cap?
As of today, MaxCyte market cap is 238.37M.
What Is MaxCyte's Earnings Per Share (TTM)?
The MaxCyte EPS (TTM) is -0.40.
When Is the Next MaxCyte Earnings Date?
MaxCyte will release its next earnings report on 05 Aug 2025.
From a Technical Analysis Perspective, Is MXCT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has MaxCyte Stock Split?
MaxCyte has split 0 times.
How Many Employees Does MaxCyte Have?
MaxCyte has 114 employees.
What is the current trading status of MaxCyte (MXCT)?
As of 23 Jul 2025, MaxCyte (MXCT) is trading at a price of 2.24, with a previous close of 2.24. The stock has fluctuated within a day range of 2.12 to 2.30, while its 52-week range spans from 2.00 to 5.20.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.